Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.

CompletedOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

December 27, 2023

Conditions

Soluble Urokinase Plasminogen Activation ReceptorAbdominal PainEmergency DepartmentMortality

Interventions

DIAGNOSTIC_TEST

Soluble Urokinase Plasminogen Activation Receptor measurement

In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.

Trial Locations (1)

CHU of Poitiers, Poitiers

All Listed Sponsors

lead

Poitiers University Hospital

OTHER